Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 78 results found. Search for [ COVID-19 vaccine Pfizer late-stage trials ]

Results 1 to 21 of 78
BusinessToday.In
November 24, 2020
Vardhan says it makes no sense to consider Pfizer as pharma major is yet to get approval in the US. After requisite approvals, US pharma major will have to cater to needs of its own country's population first


Reuters
November 22, 2020
On Monday, an EU official involved in the talks said the European Commission wanted to reach a deal with Moderna for the supply of millions of doses of its vaccine candidate for a price below $25 per dose


BusinessToday.In
November 19, 2020
Pharmaceutical industry giant Pfizer and its German partner BioNTech had stated on November 18 that their vaccine candidate was 95 per cent effective in preventing COVID-19 infections during late-stage trials


BusinessToday.In
November 19, 2020
Late-stage trials of the Oxford vaccine are still awaited but hopes are high that it'll also join frontrunners' league with Pfizer, Moderna and Russia's Sputnik V


BusinessToday.In
New Delhi, November 19, 2020
US pharma giants Pfizer and Moderna have released the results of clinical trials of their respective experimental coronavirus vaccines, with both reporting an efficacy of over 90 per cent. The Russian vaccine, Sputnik V has also shown encouraging results in the late-stage trials. By when will the first coronavirus vaccine be ready? Watch as the experts explain the status of the global COVID-19 vaccines, with their existing challenges.Also Read: Pfizer share rises nearly 7% after firm says COVID-19 vaccine 95% effective


Manali
November 18, 2020
Defining the four attributes, Serum Institute of India CEO Adar Poonawalla posted that a good vaccine must be safe, should offer long-term protection against targeted disease, can be transported and stored at a manageable temperature, and lastly, affordable


Reuters
November 18, 2020
The link will send users directly to authoritative COVID-19 vaccine information from a third-party source like the Centers for Disease Control and Prevention or the World Health Organization (WHO)


Reuters
November 18, 2020
Johnson & Johnson's chief scientist said the drugmaker must provide safety data to the US Food and Drug Administration for at least one-half of trial participants for a duration of two months after they receive the vaccine


Reuters
November 18, 2020
The Sinovac findings, published in a peer-reviewed paper in medical journal The Lancet Infectious Diseases, came from results in Phase I and Phase II clinical trials in China involving more than 700 participants


BusinessToday.In
New Delhi, November 17, 2020
Moderna announced on Monday that its experimental COVID-19 vaccine 'mRNA-1273' was 94.5 per cent effective in preventing coronavirus. The statement was issued on the basis of interim data from a late-stage clinical trial. The announcement makes Moderna the second US-based pharmaceutical giant to have reported exceedingly hopeful results from clinical trials of their respective coronavirus vaccine candidates, after Pfizer vaccine. Watch the video for more.


BusinessToday.In
November 17, 2020
These early efficacy figures don't tell the whole story. The data results are based on a relatively smaller group of participants who received these vaccine shots. The actual efficacy could be known only after the final results are out as Phase 3 clinical trials end


Reuters
November 17, 2020
Interim data from a late-stage trial indicated Moderna's vaccine was 94.5% effective in preventing COVID-19


BusinessToday.In
November 17, 2020
The early results provide strong signals that the coronavirus vaccine could prevent a majority of disease when large groups of people are vaccinated. However, the actual efficacy could be known only after the final results are out once the stage 3 trials end


Reuters
November 17, 2020
The Hyderabad-based firm initiated phase I and phase II trials of its vaccine candidate after getting the green signal from the Drugs Controller General of India


BusinessToday.In
November 16, 2020
Moderna stated that its COVID-19 vaccine candidate remains stable for 30 days at 2-degree Celsius to 8-degree Celsius, the temperature of a standard home or medical refrigerator


Reuters
November 16, 2020
The U.S. drugmaker plans to enrol up to 30,000 participants for the study and run it in parallel with a one-dose trial with as many as 60,000 volunteers that began in September


Aseem Thapliyal
November 15, 2020
Over the past week, the 30-share BSE Sensex jumped 1,744.92 points or 4.16 per cent


BusinessToday.In
November 15, 2020
As per Anthony Fauchi, the Pfizer's vaccine distribution process in the US will start in December. This, he said, will also help reduce the daily spike in coronavirus cases, which reached 1.9 lakh this week


BusinessToday.In
November 13, 2020
Pfizer and BioNTech recently announced that their vaccine candidate BNT162b2 has shown over 90 per cent efficacy in preventing coronavirus, as per data from Phase III clinical trials


BusinessToday.In
November 13, 2020
On nations hoarding vaccine stocks to meet their requirements first, Dmitriev said it is not about vaccine nationalism and that India is an important partner


PAGES 1 OF 4  1234